CytoMed Therapeutics (GDTC) Share-based Compensation (2022 - 2025)
CytoMed Therapeutics (GDTC) posted Share-based Compensation of $300728.0 for Q2 2023, up 22.18% sequentially from $246132.0 in Q2 2022, and up 22.18% YoY from $246132.0 in Q2 2022.
CytoMed Therapeutics (GDTC) Share-based Compensation (2022 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Share-based Compensation for 2 years, with the latest figure at $300728.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.54 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.41 Bn | 54.27 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | - |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 448,327.00 |
| Jun 30, 2025 | 448,327.00 |
| Jun 30, 2023 | 300,728.00 |
| Jun 30, 2023 | 300,728.00 |
| Jun 30, 2022 | 246,132.00 |
| Jun 30, 2022 | 246,132.00 |